open access

Ahead of print
Review Article
Published online: 2021-04-09
Get Citation

Post-percutaneous coronary intervention angina: From physiopathological mechanisms to individualized treatment

Leonardo De Luca, Giuseppe M.C. Rosano, Ilaria Spoletini
DOI: 10.5603/CJ.a2021.0042
·
Pubmed: 33843042

open access

Ahead of print
Review articles
Published online: 2021-04-09

Abstract

Chronic ischemic heart disease (IHD) is a multifactorial disease with different underlying pathogenetic mechanisms. Percutaneous coronary intervention (PCI) is widely used in patients with IHD in order to reduce angina recurrence. However, after complete or incomplete revascularization procedures, patients may still present anginal symptoms, with a detrimental impact on quality of life and prognosis.

This review summarizes the pathogenic mechanisms and the main challenges encountered in the diagnosis and management of post-PCI angina.

Abstract

Chronic ischemic heart disease (IHD) is a multifactorial disease with different underlying pathogenetic mechanisms. Percutaneous coronary intervention (PCI) is widely used in patients with IHD in order to reduce angina recurrence. However, after complete or incomplete revascularization procedures, patients may still present anginal symptoms, with a detrimental impact on quality of life and prognosis.

This review summarizes the pathogenic mechanisms and the main challenges encountered in the diagnosis and management of post-PCI angina.

Get Citation

Keywords

angina, ischemic heart disease, percutaneous coronary intervention, medical therapy, quality of life

About this article
Title

Post-percutaneous coronary intervention angina: From physiopathological mechanisms to individualized treatment

Journal

Cardiology Journal

Issue

Ahead of print

Article type

Review Article

Published online

2021-04-09

DOI

10.5603/CJ.a2021.0042

Pubmed

33843042

Keywords

angina
ischemic heart disease
percutaneous coronary intervention
medical therapy
quality of life

Authors

Leonardo De Luca
Giuseppe M.C. Rosano
Ilaria Spoletini

References (48)
  1. Sanchis-Gomar F, Perez-Quilis C, Leischik R, et al. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016; 4(13): 256.
  2. Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
  3. Kureshi F, Shafiq A, Arnold SV, et al. The prevalence and management of angina among patients with chronic coronary artery disease across US outpatient cardiology practices: insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study. Clin Cardiol. 2017; 40(1): 6–10.
  4. Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation. 2014; 129(14): 1493–1501.
  5. Peterson E. The burden of angina pectoris and its complications [corrected]. Clin Cardiol. 2007; 30(2 Suppl 1): I10–I15.
  6. Roth GA, Johnson CO, Abate KH, et al. The burden of cardiovascular diseases among US states, 1990-2016. JAMA Cardiol. 2018; 3(5): 375–389.
  7. Steg PG, Greenlaw N, Tendera M, et al. Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease (CLARIFY) Investigators. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. JAMA Intern Med. 2014; 174(10): 1651–1659.
  8. Kwok CS, Shah B, Al-Suwaidi J, et al. Timing and causes of unplanned readmissions after percutaneous coronary intervention: insights from the nationwide readmission database. JACC Cardiovasc Interv. 2019; 12(8): 734–748.
  9. Huqi A, Morrone D, Guarini G, et al. Stress testing after complete and successful coronary revascularization. Can J Cardiol. 2016; 32(8): 986.e23–986.e29.
  10. Ben-Yehuda O, Kazi DS, Bonafede M, et al. Angina and associated healthcare costs following percutaneous coronary intervention: A real-world analysis from a multi-payer database. Catheter Cardiovasc Interv. 2016; 88(7): 1017–1024.
  11. Crea F, Bairey Merz CN, Beltrame JF, et al. Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. Eur Heart J. 2019; 40(29): 2455–2462.
  12. Sara JD, Widmer RJ, Matsuzawa Y, et al. Prevalence of coronary microvascular dysfunction among patients with chest pain and nonobstructive coronary artery disease. JACC Cardiovasc Interv. 2015; 8(11): 1445–1453.
  13. Marzilli M, Merz CN, Boden WE, et al. Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! J Am Coll Cardiol. 2012; 60(11): 951–956.
  14. Ford TJ, Stanley B, Good R, et al. Stratified medical therapy using invasive coronary function testing in angina: the CorMicA trial. J Am Coll Cardiol. 2018; 72(23 Pt A): 2841–2855.
  15. Fearon WF, Nishi T, De Bruyne B, et al. Clinical outcomes and cost-effectiveness of fractional flow reserve-guided percutaneous coronary intervention in patients with stable coronary artery disease: three-year follow-up of the FAME 2 trial (fractional flow reserve versus angiography for multivessel evaluation). Circulation. 2018; 137(5): 480–487.
  16. Nunen Lv, Zimmermann F, Tonino P, et al. Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. Lancet. 2015; 386(10006): 1853–1860.
  17. Stefanini GG, Windecker S. Stent thrombosis: no longer an issue with newer-generation drug-eluting stents? Circ Cardiovasc Interv. 2012; 5(3): 332–335.
  18. Gaglia MA, Torguson R, Lipinski MJ, et al. Frequency of angina pectoris after percutaneous coronary intervention and the effect of metallic stent type. Am J Cardiol. 2016; 117(4): 526–531.
  19. Ellis SG, Kereiakes DJ, Metzger DC, et al. ABSORB III Investigators. Everolimus-Eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015; 373(20): 1905–1915.
  20. Stone GW, Maehara A, Lansky AJ, et al. PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011; 364(3): 226–235.
  21. Rosner GF, Kirtane AJ, Genereux P, et al. Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Circulation. 2012; 125(21): 2613–2620.
  22. Généreux P, Palmerini T, Caixeta A, et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. J Am Coll Cardiol. 2012; 59(24): 2165–2174.
  23. Dauerman HL. Reasonable incomplete revascularization. Circulation. 2011; 123(21): 2337–2340.
  24. Alexander KP, Weisz G, Prather K, et al. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the ranolazine for incomplete vessel revascularization (RIVER-PCI) trial. Circulation. 2016; 133(1): 39–47.
  25. Weisz G, Généreux P, Iñiguez A, et al. RIVER-PCI investigators. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016; 387(10014): 136–145.
  26. Fox K, Ford I, Steg PG, et al. BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008; 372(9641): 817–821.
  27. Antoni ML, Boden H, Delgado V, et al. Relationship between discharge heart rate and mortality in patients after acute myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J. 2012; 33(1): 96–102.
  28. Giannoglou GD, Chatzizisis YS, Zamboulis C, et al. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol. 2008; 126(3): 302–312.
  29. Kop WJ, Verdino RJ, Gottdiener JS, et al. Changes in heart rate and heart rate variability before ambulatory ischemic events(1). J Am Coll Cardiol. 2001; 38(3): 742–749.
  30. Androulakis E, Tousoulis D, Papageorgiou N, et al. Heart rate as a therapeutic target in angina pectoris. Curr Pharm Des. 2013; 19(9): 1562–1568.
  31. Steg P, Ferrari R, Ford I, et al. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One. 2012; 7(5): e36284.
  32. Ferrari R, Camici PG, Crea F, et al. Expert consensus document: A 'diamond' approach to personalized treatment of angina. Nat Rev Cardiol. 2018; 15(2): 120–132.
  33. Sorbets E, Steg PG, Young R, et al. CLARIFY investigators. Beta-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019; 40(18): 1399–1407.
  34. Ferrari R, Pavasini R, Camici PG, et al. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J. 2019; 40(2): 190–194.
  35. Pavasini R, Camici PG, Crea F, et al. Anti-anginal drugs: systematic review and clinical implications. Int J Cardiol. 2019; 283: 55–63.
  36. Zarifis J, Grammatikou V, Kallistratos M, et al. Antianginal efficacy of ivabradine in patients with history of coronary revascularization. Angiology. 2017; 68(1): 10–18.
  37. Calcagno S, Infusino F, Dettori O, et al. Effects of ivabradine on residual myocardial ischemia after PCI evaluated by stress echocardiography. Cardiol Res Pract. 2019; 2019: 9185876.
  38. Chen J, Zhou S, Jin J, et al. Chronic treatment with trimetazidine after discharge reduces the incidence of restenosis in patients who received coronary stent implantation: a 1-year prospective follow-up study. Int J Cardiol. 2014; 174(3): 634–639.
  39. Ferrari R, Ford I, Fox K, et al. A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristics. Am Heart J. 2019; 210: 98–107.
  40. Spertus JA, Maron DJ, Cohen DJ, et al. Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Investigators and Coordinators. Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial. Circ Cardiovasc Qual Outcomes. 2013; 6(4): 409–418.
  41. Hamon M, Lemesle G, Meurice T, et al. Elective coronary revascularization procedures in patients with stable coronary artery disease: incidence, determinants, and outcome (from the CORONOR study). JACC Cardiovasc Interv. 2018; 11(9): 868–875.
  42. Maron DJ, Hochman JS, Maron DJ, et al. ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020; 382(15): 1395–1407.
  43. Spertus JA, Jones PG, Maron DJ, et al. ISCHEMIA Research Group. Health-Status outcomes with invasive or conservative care in coronary disease. N Engl J Med. 2020; 382(15): 1408–1419.
  44. Fanaroff AC, Kaltenbach LA, Peterson ED, et al. Management of persistent angina after myocardial infarction treated with percutaneous coronary intervention: insights from the TRANSLATE-ACS study. J Am Heart Assoc. 2017; 6(10).
  45. De Luca L, Temporelli PL, Lucci D, et al. START Investigators. Current management and treatment of patients with stable coronary artery diseases presenting to cardiologists in different clinical contexts: A prospective, observational, nationwide study. Eur J Prev Cardiol. 2018; 25(1): 43–53.
  46. Berliner D, Maier LS, Wollenberg U, et al. Clinical care for patients with recurrent myocardial ischemia in Germany-the VOICES trial. J Thorac Dis. 2018; 10(Suppl 15): S1777–S1784.
  47. Arnold SV, Grodzinsky A, Gosch KL, et al. Predictors of physician under-recognition of angina in outpatients with stable coronary artery disease. Circ Cardiovasc Qual Outcomes. 2016; 9(5): 554–559.
  48. Ambrosio G, Collins P, Dechend R, et al. Sta Ble Angina: Pe Rcept Ion of Nee Ds, Quality of Life and Mana Gem Ent of Patients (BRIDGE Study)-A Multinational European Physician Survey. Angiology. 2019; 70(5): 397–406.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl